TY - JOUR
T1 - Recommendations for cerebrospinal fluid Alzheimer's disease biomarkers in the diagnostic evaluation of mild cognitive impairment
AU - Herukka, Sanna-Kaisa
AU - Simonsen, Anja Hviid
AU - Andreasen, Niels
AU - Baldeiras, Ines
AU - Bjerke, Maria
AU - Blennow, Kaj
AU - Engelborghs, Sebastiaan
AU - Frisoni, Giovanni B.
AU - Gabryelewicz, Tomasz
AU - Galluzzi, Samantha
AU - Handels, Ron
AU - Kramberger, Milica G.
AU - Kulczynska, Agnieszka
AU - Luis Molinuevo, Jose
AU - Mroczko, Barbara
AU - Nordberg, Agneta
AU - Oliveira, Catarina Resende
AU - Otto, Markus
AU - Rinne, Juha O.
AU - Rot, Uros
AU - Saka, Esen
AU - Soininen, Hilkka
AU - Struyfs, Hanne
AU - Suardi, Silvia
AU - Visser, Pieter Jelle
AU - Winblad, Bengt
AU - Zetterberg, Henrik
AU - Waldemar, Gunhild
PY - 2017/3
Y1 - 2017/3
N2 - This article presents recommendations, based on the Grading of Recommendations, Assessment, Development, and Evaluation method, for the clinical application of cerebrospinal fluid (CSF) amyloid-beta(1-42), tau, and phosphorylated tau in the diagnostic evaluation of patients with mild cognitive impairment (MCI). The recommendations were developed by a multidisciplinary working group and based on the available evidence and consensus from focused group discussions for 1) prediction of clinical progression to Alzheimer's disease (AD) dementia, 2) cost-effectiveness, 3)interpretation of results, and 4) patient counseling. The working group recommended using CSF AD biomarkers in the diagnostic workup of MCI patients, after prebiomarker counseling, as an add-on to clinical evaluation to predict functional decline or conversion to AD dementia and to guide disease management. Because of insufficient evidence, it was uncertain whether CSF AD biomarkers outperform imaging biomarkers. Furthermore, the working group provided recommendations for interpretation of ambiguous CSF biomarker results and for pre-and post-biomarker counseling. (C) 2016 The Authors. Published by Elsevier Inc. on behalf of the Alzheimer's Association.
AB - This article presents recommendations, based on the Grading of Recommendations, Assessment, Development, and Evaluation method, for the clinical application of cerebrospinal fluid (CSF) amyloid-beta(1-42), tau, and phosphorylated tau in the diagnostic evaluation of patients with mild cognitive impairment (MCI). The recommendations were developed by a multidisciplinary working group and based on the available evidence and consensus from focused group discussions for 1) prediction of clinical progression to Alzheimer's disease (AD) dementia, 2) cost-effectiveness, 3)interpretation of results, and 4) patient counseling. The working group recommended using CSF AD biomarkers in the diagnostic workup of MCI patients, after prebiomarker counseling, as an add-on to clinical evaluation to predict functional decline or conversion to AD dementia and to guide disease management. Because of insufficient evidence, it was uncertain whether CSF AD biomarkers outperform imaging biomarkers. Furthermore, the working group provided recommendations for interpretation of ambiguous CSF biomarker results and for pre-and post-biomarker counseling. (C) 2016 The Authors. Published by Elsevier Inc. on behalf of the Alzheimer's Association.
KW - Alzheimer's disease
KW - Biomarkers
KW - CSF
KW - Diagnostics
KW - GRADE
KW - Mild cognitive impairment
KW - Recommendations
KW - POSITRON-EMISSION-TOMOGRAPHY
KW - APOLIPOPROTEIN-E GENOTYPE
KW - ASSOCIATION WORKGROUPS
KW - PHOSPHORYLATED-TAU
KW - NATIONAL INSTITUTE
KW - COST-EFFECTIVENESS
KW - GRADING QUALITY
KW - CSF BIOMARKERS
KW - DEMENTIA
KW - METAANALYSIS
U2 - 10.1016/j.jalz.2016.09.009
DO - 10.1016/j.jalz.2016.09.009
M3 - Article
C2 - 28341066
SN - 1552-5260
VL - 13
SP - 285
EP - 295
JO - Alzheimer's & Dementia
JF - Alzheimer's & Dementia
IS - 3
ER -